Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (1146)	1/15/1998 11:02:00 AM
From: Dakota12	Read Replies (1) \| Respond to of 1894

From the press release, "Other strategic partners will contribute capital AND A COMMITMENT FOR TECHNOLOGY." This deal cannot be valued simply as you have stated. The "Y" you refer too must include the technology received. This technology may turn out to be quite valuable. But, right now we have no way of putting a price on it.

To: Sigmund who wrote (1146)	1/15/1998 11:08:00 AM
From: Frank Buck	Read Replies (1) \| Respond to of 1894

Sigmund, Sounds to me like AccuMed has cut away 50% of the <fat>-(R&D cost) sold half of it, there-by increasing needed net-asset value, (with-out dilution) and kept the core (muscle) of the current revenue producing side of the business. That fat-sell-off equates to retaining 50% of the future expected revenues from that currently non-revenue producing "hole in the pocket". But b/c of the synergies of the newly created venture, the expected future revenue from the newly created R&D products (being developed) should be higher and therefore recompensate (future-value) for the initial low price (present-value). If one is to believe that the expected future revenue capabilities of NewCo are to be inherently larger then if AccuMed went it alone, the deal is reasonably valued. The no dilution aspect and the increase in present net-value (present value) account for something. This also takes the guesswork (reduces by half) how AccuMed was going to finance the current activities of their ongoing R&D and still become profitable this year. I do believe the analysts will like it! Unfortunately they won't be able to provide an "initial strong-buy" as we have that from them in spades. They can however, "reiterate" a strong-buy, for what it is worth. My concern is how is this going to affect the existing Leica relationship. Frank